OSLM
Outcome Studies
in Laboratory Medicine
guest
👤
Learn more about this platform
c
Categories
p
Projects
Trial protocol
Highlighted
Study Design
RCT
Cluster RCT
Observational
Model
Meta-analysis
Review
Guideline
Outcomes
Change patient management
Clinical outcomes
Economics
Operational efficiencies
Patient-centeredness
Safety
Guide Policy Making
Other
Uncategorized
Antibiotic Guidance
ACT Guided Heparinization
Cancer
COVID-19
Cardiovascular Disease
Diabetes
HIV POCT
Inflammatory Bowel Disease
Liver Disease
Kidney Disease
Newborn Screening
MALDI-TOF MS For Microorganism Identification
Preeclampsia
Pharmacogenetic and Pharmacogenomics
Therapeutic drug monitoring
Viscoelastic Testing
Please contact us for any suggestions
Zhen Zhao
Smeralda Skenderaj
Search
Search
Categories:
Clinical outcomes
Model
19 Publications
found
Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission.
b
Annals of internal medicine
June 1, 2021
p
COVID-19
c
Clinical outcomes
Economics
Guide Policy Making
Highlighted
Model
Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis.
b
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
June 1, 2021
p
Inflammatory Bowel Disease
c
Clinical outcomes
Economics
Highlighted
Model
Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study.
b
The Lancet. Public health
March 1, 2021
p
COVID-19
c
Clinical outcomes
Economics
Highlighted
Model
Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study.
b
The Lancet. Infectious diseases
December 1, 2020
p
COVID-19
c
Clinical outcomes
Model
Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
b
Gut
April 1, 2020
p
Inflammatory Bowel Disease
c
Clinical outcomes
Economics
Model
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
b
Journal of medical economics
April 1, 2019
p
Cancer
c
Change patient management
Clinical outcomes
Model
Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
b
Lung cancer (Amsterdam, Netherlands)
May 1, 2015
p
Cancer
c
Clinical outcomes
Economics
Model
A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis.
b
Lung cancer (Amsterdam, Netherlands)
December 1, 2013
p
Cancer
c
Clinical outcomes
Economics
Model
The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.
b
British journal of cancer
March 13, 2012
p
Cancer
c
Clinical outcomes
Economics
Model
Previous Page
1
2
